摘要
目的探讨氨氯地平贝那普利对糖尿病合并高血压患者动态血压的影响及肾脏保护作用。方法 105例糖尿病合并高血压患者随机分为3组,每组35例,A组单用氨氯地平治疗,剂量10 mg/次,每日1次,每日6:00—8:00服药;B组单用盐酸贝那普利片进行治疗,剂量20 mg/次,每日1次,每日6:00—8:00服药;C组应用氨氯地平贝那普利片进行治疗,口服,15 mg/次,每日1次,每日6:00—8:00服药,均持续用药3个月。对比3组患者治疗前后的动态血压指标及肾功能指标变化,并观察两组治疗期间的不良反应。结果 3组患者用药1、3个月的24 h平均收缩压(SBP)、舒张压(DBP)值均较用药前降低,同组治疗前后比较差异有统计学意义(P<0.05);且C组用药1、3个月的24 h平均SBP、DBP值均显著低于A、B两组,组间差异有统计学意义(P<0.05)。3组患者用药1、3个月的尿微量白蛋白排泄率比较有显著性差异,同组治疗前后比较差异有统计学意义(P<0.05);且C组用药1、3个月的尿微量白蛋白排泄率均显著低于A、B两组,差异有统计学意义(P<0.05)。3组患者的不良反应均较轻微,未进行特殊处理,不影响持续治疗。3组的不良反应发生率对比无显著差异。结论氨氯地平贝那普利治疗糖尿病合并高血压,能够有效降低血压水平改善临床症状,发挥肾脏保护作用,且无明显不良反应。
Objective To explore the effects of amlodipine benazepril treatment of diabetic hypertension on ambulatory blood pressure and renal protection. Methods 105 patients with diabetes mellitus were randomly divided into three groups（n = 35）. Group A was treated with amlodipine alone. Group B was treated with benazepril alone. Group C was treated with amlodipine benazepril. To compare the ambulatory blood pressure index and renal function index changes of three groups before and after treatment. Results The 24 h mean SBP and DBP of the three groups were significantly lower than those of the control group after treatment 1 month and 3 months（P 〈 0.05）, and the difference was significant（P 〈 0.05）. The 24 h mean SBP and DBP of group C were significantly lower than those of group A and group B after treatment 1 month and 3 months（P 〈 0.05）.Three groups of patients with urinary microalbumin excretion rate was significantly different after treatment 1 month and 3 months, and the rate of urinary albumin excretion in group C was significantly lower than that in group A and B after treatment 1 month and 3 months（P 〈 0.05）. The adverse reactions of the three groups were mild, and no special treatment was carried out, which did not affect the continuous treatment. There was no significant difference in the incidence of adverse reactions between the three groups. Conclusion Amlodipine benazepril treatment of diabetic hypertension can effectively reduce the level of blood pressure to improve clinical symptoms, play a protective role in the kidney, and no significant adverse reactions.
作者
冯姝敏
FENG Shumin(People＇s Liberation Army 105 Hospital, Hefei 230000, China)
出处
《药物评价研究》
CAS
2018年第5期852-855,共4页
Drug Evaluation Research
